Alnylam Pharmaceuticals ROE - Return on Equity 2010-2024 | ALNY

Alnylam Pharmaceuticals return on equity for the quarter ending September 30, 2024 was 324.09.

  • Alnylam Pharmaceuticals average return on equity for 2023 was 556.48, a 208.06% decline from 2022.
  • Alnylam Pharmaceuticals average return on equity for 2022 was -514.98, a 458.06% decline from 2021.
  • Alnylam Pharmaceuticals average return on equity for 2021 was -92.28, a 47.2% increase from 2020.

Roe - return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.

Alnylam Pharmaceuticals ROE - Return on Equity 2010-2024 | ALNY

  • Alnylam Pharmaceuticals average return on equity for 2023 was 556.48, a 208.06% decline from 2022.
  • Alnylam Pharmaceuticals average return on equity for 2022 was -514.98, a 458.06% decline from 2021.
  • Alnylam Pharmaceuticals average return on equity for 2021 was -92.28, a 47.2% increase from 2020.

Roe - return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.